Tandem, TypeZero announce license agreement for artificial pancreas system
Tandem Diabetes Care, Inc., and TypeZero Technologies, LLC, have entered into a license agreement allowing Tandem to integrate TypeZero’s artificial pancreas technology into a next-generation t:slim Insulin Pump, according to a press release.
Tandem is a medical device company that manufactures touchscreen insulin pumps. TypeZero is a digital health and personalized medicine company whose artificial pancreas technology includes a series of treat-to-target algorithms. The companies hope to expedite clinical research needed to develop Tandem’s closed-loop artificial pancreas system.
“This agreement with TypeZero is a significant step in our shared vision to bring a best-in-class, closed-loop artificial pancreas system to the diabetes community as quickly as possible,” Kim Blickenstaff, president and CEO of Tandem, said in the release. “We look forward to working the TypeZero on this project to deliver simple-to-use artificial pancreas solutions that can improve treatment outcomes for people with diabetes.”
“We believe that bringing our artificial pancreas technology together with Tandem’s innovative insulin pump platform will revolutionize the way patients manage their diabetes,” Chad Rogers, TypeZero Technologies founder and CEO, said in the release.
The terms of the agreement anticipate that Tandem’s t:slim Insulin Pump will be used alongside TypeZero’s artificial pancreas technology in the International Diabetes Closed Loop Trial, funded by the National Institute of Health, which is scheduled to begin later this year.